Autologus fat transfer for restoration of facial contour in "Progressive facial hemiatrophy"

Deshmukh, Supriya P; Dogra, Bharat Bhushan; Deo, Kirti

doi:10.4103/0378-6323.102398

Cited by 6 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Months Effective High aesthetic satisfaction Avelar et al (2010) 1 y Good Satisfied Castro-Govea et al (2012) 1 y Satisfactory Cervelli and Gentile (2009) 1-2 y Satisfied Chang et al (2013) 1 y Improved None Clauser et al (2010) Not specified Good Satisfied Cortese et al (2000) Not specified Very good Increased reabsorption in areas of high mobility Deshmukh et al (2012) Not specified Ersek et al (1998) 7 mo Symmetrical appearance Grimaldi et al (2008) Not specified Effective Satisfied Guerrerosantos et al (2007) 1-8 y Improved Satisfied Hu et al (2011) Not specified Improved Hunstad et al (2011) 14 y Successful Hypertrophy of transplanted fat with weight gain Kanchwala et al (2003) 3 y Excellent Koh et al (2012) 1.5 y Excessive volume loss with weight loss in one case Liu and Cohen (2010) 1 y Successful Longobardi et al (2011) 6 y Excellent Moscona et al (1989) 18 mo Satisfied Edema with injections, minimal reabsorption Onesti et al (2009) 1 y Good Satisfied Pagnoni et al (2012) 1 y Good Edema with injections, minimal reabsorption Palmero et al (2010) Not specified Fat necrosis Raposo-Amaral et al (2013) 1-4 y Satisfactory Roddi et al (1994) 3-18 mo Minimal reabsorption Saccomanno et al (1997) 2 y None Slack et al (2012) 5-28 y Improved symmetry Sterodimas et al (2009) 13 mo Improved aesthetics Satisfied Edema with injections Tiryaki et al (2011) 18 mo Satisfied Subcutaneous ecchymosis Tobin and Middleton (1989) 9 mo Improved aesthetics Satisfied None Xie et al (2007) 3 …”

mentioning

confidence: 98%

Evaluating Autologous Lipofilling for Parry-Romberg Syndrome–Associated Defects: A Systematic Literature Review and Case Report

Rodby

Kaptein

Roring

et al. 2016

The Cleft Palate Craniofacial Journal

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 98%

Evaluating Autologous Lipofilling for Parry-Romberg Syndrome–Associated Defects: A Systematic Literature Review and Case Report

Rodby

Kaptein

Roring

et al. 2016

The Cleft Palate Craniofacial Journal

View full text Add to dashboard Cite

show abstract

“…A recent study reviews the surgical treatment options for Parry–Romberg syndrome and ECDS and describes the debate with regard to timing of these procedures [36]. Autologous fat grafting in ECDS is reported in multiple case reports and series [216–221]. Lastly, one case report describes correction for limb-length discrepancy in linear morphea of a lower extremity [222].…”

Section: Treatmentmentioning

confidence: 99%

Morphea and Eosinophilic Fasciitis: An Update

et al. 2017

View full text Add to dashboard Cite

Morphea, also known as localized scleroderma, encompasses a group of idiopathic sclerotic skin diseases. The spectrum ranges from relatively mild phenotypes, which generally cause few problems besides local discomfort and visible disfigurement, to subtypes with severe complications such as joint contractures and limb length discrepancies. Eosinophilic fasciitis (EF, Shulman syndrome) is often regarded as belonging to the severe end of the morphea spectrum. The exact driving mechanisms behind morphea and EF pathogenesis remain to be elucidated. However, extensive extracellular matrix formation and autoimmune dysfunction are thought to be key pathogenic processes. Likewise, these processes are considered essential in systemic sclerosis (SSc) pathogenesis. In addition, similarities in clinical presentation between morphea and SSc have led to many theories about their relatedness. Importantly, morphea may be differentiated from SSc based on absence of sclerodactyly, Raynaud’s phenomenon, and nailfold capillary changes. The diagnosis of morphea is often based on characteristic clinical findings. Histopathological evaluation of skin biopsies and laboratory tests are not necessary in the majority of morphea cases. However, full-thickness skin biopsies, containing fascia and muscle tissue, are required for the diagnosis of EF. Monitoring of disease activity and damage, especially of subcutaneous involvement, is one of the most challenging aspects of morphea care. Therefore, data harmonization is crucial for optimizing standard care and for comparability of study results. Recently, the localized scleroderma cutaneous assessment tool (LoSCAT) has been developed and validated for morphea. The LoSCAT is currently the most widely reported outcome measure for morphea. Care providers should take disease subtype, degree of activity, depth of involvement, and quality-of-life impairments into account when initiating treatment. In most patients with circumscribed superficial subtypes, treatment with topical therapies suffices. In more widespread disease, UVA1 phototherapy or systemic treatment with methotrexate (MTX), with or without a systemic corticosteroid combination, should be initiated. Disappointingly, few alternatives for MTX have been described and additional research is still needed to optimize treatment for these debilitating conditions. In this review, we present a state-of-the-art flow chart that guides care providers in the treatment of morphea and EF.

show abstract

“…Plastic surgery may be considered in cases of linear localized scleroderma with face involvement (localized scleroderma en coup de sabre, progressive facial hemiatrophy) in order to improve facial contour [2,3,7]. The best therapeutic effects are achieved with autologous fat transplants [24]. Subcutaneous tissue is a widely accessible, biocompatible and inexpensive filler which can be used for repeated treatments [24].…”

Section: Alternatywne Formy Terapii Zabiegi Chirurgicznementioning

confidence: 99%

“…The best therapeutic effects are achieved with autologous fat transplants [24]. Subcutaneous tissue is a widely accessible, biocompatible and inexpensive filler which can be used for repeated treatments [24]. The application of synthetic materials such as silicone, hyaluronic acid or lactic acid is associated with the risk of inflammatory reaction, dyspigmentation and scarring [24].…”

Section: Alternatywne Formy Terapii Zabiegi Chirurgicznementioning

confidence: 99%

“…Subcutaneous tissue is a widely accessible, biocompatible and inexpensive filler which can be used for repeated treatments [24]. The application of synthetic materials such as silicone, hyaluronic acid or lactic acid is associated with the risk of inflammatory reaction, dyspigmentation and scarring [24]. There have also been reports of localized scleroderma en coup de sabre and progressive facial hemiatrophy corrected by cranioplasty, placement of orbital implants and injections of botulinum toxin [17].…”

Section: Alternatywne Formy Terapii Zabiegi Chirurgicznementioning

confidence: 99%

See 1 more Smart Citation

Localized scleroderma – current treatment options

Wolska-Gawron¹,

Michalska-Jakubus²,

Krasowska³

2017

View full text Add to dashboard Cite

Localized scleroderma (morphea) is a connective tissue disease that affects the skin, subcutaneous tissue and underlying tissues including the fasciae, muscles and bones. The treatment of localized scleroderma depends on the clinical form of the disease, its severity/activity, extent of skin lesions and patient's age. Patients with limited skin involvement caused by morphea require topical therapy with glucocorticoids, calcineurin inhibitors, calcipotriol or UVA/PUVA phototherapy. More severe variants of localized scleroderma with extensive tissue involvement require immediate systemic therapy with glucocorticoids and/or methotrexate, or mycophenolate mofetil. According to recent reports, attempts have also been taken, with variable clinical outcomes, to treat localized scleroderma topically with pirfenidone and imiquimod, systemically with tacrolimus and cyclosporine; and with fractional CO 2 laser, photodynamic therapy and autologous fat transfer. The article presents current therapeutic methods of localized scleroderma. streszczenie Twardzina ograniczona (morphea, localized scleroderma) jest chorobą tkanki łącznej, która manifestuje się zajęciem skóry, tkanki podskórnej oraz tkanek leżących poniżej-powięzi, mięśni lub kości. Leczenie twardziny ograniczonej zależy od postaci klinicznej, nasilenia lub aktywności choroby, rozległości wykwitów oraz wieku pacjenta. Pacjenci z ograniczonym zajęciem skóry w przebiegu morphea wymagają terapii miejscowej z zastosowaniem glikokortykosteroidów, inhibitorów kalcyneuryny, kalcypotriolu lub fototerapii (UVA/PUVA). W cięższych odmianach, w których dochodzi do rozległego zajęcia tkanek, należy jak najszybciej rozpocząć terapię ogólną z zastosowaniem glikokortykosteroidów i/lub metotreksatu, ewentualnie mykofenolanu mofetylu. Według najnowszych doniesień podejmowane są próby terapii twardziny ograniczonej z zastosowaniem pirfenidonu i imikwimodu miejscowo, takrolimusu i cyklosporyny ogólnie, lasera frakcyjnego CO 2 , terapii fotodynamicznej i autologicznego przeszczepu tkanki tłuszczowej z różnym efektem klinicznym. W pracy przedstawiono aktualne metody terapii twardziny ograniczonej.

show abstract

Autologus fat transfer for restoration of facial contour in "Progressive facial hemiatrophy"

Cited by 6 publications

References 5 publications

Evaluating Autologous Lipofilling for Parry-Romberg Syndrome–Associated Defects: A Systematic Literature Review and Case Report

Evaluating Autologous Lipofilling for Parry-Romberg Syndrome–Associated Defects: A Systematic Literature Review and Case Report

Morphea and Eosinophilic Fasciitis: An Update

Localized scleroderma – current treatment options

Contact Info

Product

Resources

About